Shield Therapeutics (FRA:1JS) Scaled Net Operating Assets : 0.26 (As of Jun. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Shield Therapeutics Scaled Net Operating Assets?

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Shield Therapeutics's operating assets for the quarter that ended in Jun. 2024 was €35.92 Mil. Shield Therapeutics's operating liabilities for the quarter that ended in Jun. 2024 was €24.39 Mil. Shield Therapeutics's Total Assets for the quarter that ended in Dec. 2023 was €44.75 Mil. Therefore, Shield Therapeutics's scaled net operating assets (SNOA) for the quarter that ended in Jun. 2024 was 0.26.

Shield Therapeutics Scaled Net Operating Assets Historical Data

The historical data trend for Shield Therapeutics's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shield Therapeutics Scaled Net Operating Assets Chart

Shield Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Scaled Net Operating Assets

Get a 7-Day Free Trial

0.68

0.72

0.95

0.19

0.78

Shield Therapeutics Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Scaled Net Operating Assets	Get a 7-Day Free Trial															0.65	0.24	0.71	0.51	0.26

Competitive Comparison of Shield Therapeutics's Scaled Net Operating Assets

For the Drug Manufacturers - Specialty & Generic subindustry, Shield Therapeutics's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Shield Therapeutics's Scaled Net Operating Assets Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Shield Therapeutics's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Shield Therapeutics's Scaled Net Operating Assets falls into.

Shield Therapeutics Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Shield Therapeutics's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2023 is calculated as

	Scaled Net Operating Assets (SNOA)		(A: Dec. 2023 )
=	(Operating Assets (A: Dec. 2023 )	-	Operating Liabilities (A: Dec. 2023 ))	/	Total Assets (A: Dec. 2022 )
=	(31.959	-	12.399)	/	25.127
=	0.78

where

	Operating Assets		(A: Dec. 2023 )
=	Total Assets	-	Cash, Cash Equivalents, Marketable Securities
=	44.749	-	12.79
=	31.959

	Operating Liabilities		(A: Dec. 2023 )
=	Total Liabilities	-	Long-Term Debt & Capital Lease Obligation	-	Short-Term Debt & Capital Lease Obligation
=	30.963	-	18.368	-	0.196
=	12.399

Shield Therapeutics's Scaled Net Operating Assets (SNOA) for the quarter that ended in Jun. 2024 is calculated as

	Scaled Net Operating Assets (SNOA)		(Q: Jun. 2024 )
=	(Operating Assets (Q: Jun. 2024 )	-	Operating Liabilities (Q: Jun. 2024 ))	/	Total Assets (Q: Dec. 2023 )
=	(35.917	-	24.385)	/	44.749
=	0.26

where

	Operating Assets		(Q: Jun. 2024 )
=	Total Assets	-	Cash, Cash Equivalents, Marketable Securities
=	43.441	-	7.524
=	35.917

	Operating Liabilities		(Q: Jun. 2024 )
=	Total Liabilities	-	Long-Term Debt & Capital Lease Obligation	-	Short-Term Debt & Capital Lease Obligation
=	42.938	-	18.282	-	0.271
=	24.385

Shield Therapeutics Scaled Net Operating Assets Related Terms

Thank you for viewing the detailed overview of Shield Therapeutics's Scaled Net Operating Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Shield Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shield Therapeutics PLC (FRA:1JS) » Definitions » Scaled Net Operating Assets

Comparable Companies

Traded in Other Exchanges

SHIEF:USA STX:UK

Address

Northern Design Centre, Baltic Business Quarter, Gateshead Quays, Newcastle, GBR, NE8 3DF

Website

https://www.shieldtherapeutics.com

Shield Therapeutics PLC is a commercial stage specialty pharmaceutical company focused on the development and commercialization of late-stage, hospital-focused pharmaceuticals that address areas of high unmet medical need. The company's operating segments are based on key products including PT20 and Feraccru, involves development and commercialisation of the Group's main Feraccru product, and PT20 is used in treating hyperphosphatemia, which is in its last stage of completion. The company generates maximum revenue from the Feraccru segment.

Shield Therapeutics Headlines

No Headlines